首页> 外文期刊>The Lancet >Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
【24h】

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

机译:一种针对人乳头瘤病毒16型和18型的二价L1病毒样颗粒疫苗的长达4.5年的持续疗效:一项随机对照试验的随访结果。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. Our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent HPV-16/18 L1 virus-like particle AS04 vaccine against incident and persistent infection with HPV 16 and HPV 18 and their associated cytological and histological outcomes. METHODS: We did a follow-up study of our multicentre, double-blind, randomised, placebo-controlled trial reported in 2004. We included women who originally received all three doses of bivalent HPV-16/18 virus-like particle AS04 vaccine (0.5 mL; n=393) or placebo (n=383). We assessed HPV DNA, using cervical samples, and did yearly cervical cytology assessments. We also studied the long-term immunogenicity and safety of the vaccine. FINDINGS: More than 98% seropositivity was maintained for HPV-16/18 antibodies during the extended follow-up phase. We noted significant vaccine efficacy against HPV-16 and HPV-18 endpoints: incident infection, 96.9% (95% CI 81.3-99.9); persistent infection: 6 month definition, 94.3 (63.2-99.9); 12 month definition, 100% (33.6-100). In a combined analysis of the initial efficacy and extended follow-up studies, vaccine efficacy of 100% (42.4-100) against cervical intraepithelial neoplasia (CIN) lesions associated with vaccine types. We noted broad protection against cytohistological outcomes beyond that anticipated for HPV 16/18 and protection against incident infection with HPV 45 and HPV 31. The vaccine has a good long-term safety profile. INTERPRETATION: Up to 4.5 years, the HPV-16/18 L1 virus-like particle AS04 vaccine is highly immunogenic and safe, and induces a high degree of protection against HPV-16/18 infection and associated cervical lesions. There is also evidence of cross protection.
机译:背景:针对HPV 16和HPV 18的有效疫苗预防宫颈癌将需要高水平的持续保护,以防感染和癌前病变。我们的目标是评估二价HPV-16 / 18 L1病毒样颗粒AS04疫苗对HPV 16和HPV 18的事件和持续感染及其相关的细胞学和组织学结果的长期疗效,免疫原性和安全性。方法:我们对2004年报道的多中心,双盲,随机,安慰剂对照试验进行了跟踪研究。我们纳入了最初接受全部三剂双价HPV-16 / 18病毒样颗粒AS04疫苗的女性( 0.5 mL; n = 393)或安慰剂(n = 383)。我们使用宫颈样本评估了HPV DNA,并每年进行宫颈细胞学评估。我们还研究了疫苗的长期免疫原性和安全性。结果:在延长的随访阶段中,HPV-16 / 18抗体的血清阳性率保持在98%以上。我们注意到针对HPV-16和HPV-18终点的显着疫苗效力:事件感染率为96.9%(95%CI 81.3-99.9);持续感染:6个月定义为94.3(63.2-99.9); 12个月定义,100%(33.6-100)。在对初始功效和扩展的后续研究的综合分析中,针对与疫苗类型相关的宫颈上皮内瘤变(CIN)病变的疫苗功效为100%(42.4-100)。我们注意到,除了针对HPV 16/18的预期之外,针对细胞组织学结果的广泛保护以及针对HPV 45和HPV 31的意外感染的保护。该疫苗具有良好的长期安全性。解释:长达4.5年,HPV-16 / 18 L1病毒样颗粒AS04疫苗具有高度的免疫原性和安全性,可对HPV-16 / 18感染和相关的宫颈病变提供高度的保护。也有交叉保护的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号